RPID Stock Overview
A life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Rapid Micro Biosystems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.90 |
| 52 Week High | US$1.34 |
| 52 Week Low | US$0.58 |
| Beta | 1.06 |
| 1 Month Change | -13.88% |
| 3 Month Change | 3.44% |
| 1 Year Change | 21.62% |
| 3 Year Change | -91.69% |
| 5 Year Change | n/a |
| Change since IPO | -95.79% |
Recent News & Updates
Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) Shares Leap 25% Yet They're Still Not Telling The Full Story
Nov 02
Is Rapid Micro Biosystems (NASDAQ:RPID) In A Good Position To Invest In Growth?
Oct 29Recent updates
Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) Shares Leap 25% Yet They're Still Not Telling The Full Story
Nov 02Is Rapid Micro Biosystems (NASDAQ:RPID) In A Good Position To Invest In Growth?
Oct 29A Piece Of The Puzzle Missing From Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 32% Share Price Climb
Aug 03We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate
Jun 30Rapid Micro to introduce RMBNucleus software for mold detection in pharma manufacturing
Oct 10Companies Like Rapid Micro Biosystems (NASDAQ:RPID) Are In A Position To Invest In Growth
May 09Earnings Release: Here's Why Analysts Cut Their Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Price Target To US$17.67
Mar 08We're Not Very Worried About Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate
Feb 07Shareholder Returns
| RPID | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -1.3% | -0.5% | -1.1% |
| 1Y | 21.6% | -5.9% | 22.4% |
Return vs Industry: RPID exceeded the US Life Sciences industry which returned -4.9% over the past year.
Return vs Market: RPID underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| RPID volatility | |
|---|---|
| RPID Average Weekly Movement | 9.3% |
| Life Sciences Industry Average Movement | 9.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RPID has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RPID's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 193 | Rob Spignesi | www.rapidmicrobio.com |
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables.
Rapid Micro Biosystems, Inc. Fundamentals Summary
| RPID fundamental statistics | |
|---|---|
| Market cap | US$41.23m |
| Earnings (TTM) | -US$48.39m |
| Revenue (TTM) | US$26.17m |
1.5x
P/S Ratio-0.8x
P/E RatioIs RPID overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RPID income statement (TTM) | |
|---|---|
| Revenue | US$26.17m |
| Cost of Revenue | US$27.43m |
| Gross Profit | -US$1.26m |
| Other Expenses | US$47.13m |
| Earnings | -US$48.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.12 |
| Gross Margin | -4.82% |
| Net Profit Margin | -184.93% |
| Debt/Equity Ratio | 0% |
How did RPID perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 05:44 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rapid Micro Biosystems, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tycho Peterson | J.P. Morgan |
| Tejas Savant | Morgan Stanley |
| Daniel Arias | Stifel, Equities Research |